First-time use of bevacizumab for aggressive, metastatic hepatocellular carcinoma in an HIV/hepatitis B virus coinfected patient: A case report

Ioannis G. Baraboutis, Vassilios Papastamopoulos, Georgios Charitsis, Lazaros J. Lekakis, Michael M. Vaslamatzis, Athanasios T. Skoutelis

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

We present a case of an HIV-1 infected patient with history of chronic hepatitis B and chronic alcohol use without cirrhosis, who presented with aggressive hepatocellular carcinoma with multiple metastases. Systemic chemotherapy combined with use of bevacizumab (anti-vascular endothelium growth factor monoclonal antibody) was without effect and the patient succumbed to his disease within few weeks. To our knowledge, this is the first report in the English literature of bevacizumab use for metastatic hepatocellular carcinoma in HIV-infected patients.

Original languageEnglish (US)
Pages (from-to)472-473
Number of pages2
JournalEuropean Journal of Gastroenterology and Hepatology
Volume20
Issue number5
DOIs
StatePublished - May 1 2008
Externally publishedYes

Keywords

  • Anti-vascular endothelium growth factor
  • Bevacizumab
  • HIV/hepatitis B virus coinfection
  • Metastatic hepatocellular carcinoma

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'First-time use of bevacizumab for aggressive, metastatic hepatocellular carcinoma in an HIV/hepatitis B virus coinfected patient: A case report'. Together they form a unique fingerprint.

  • Cite this